Companies that own Incyte Corp.
Baker Bros. Advisors LP
34,251,034
16.11%
20,283
16.46%
06/30/2018
The Vanguard Group, Inc.
17,997,794
8.47%
110,319
0.04%
06/30/2018
Wellington Management Co. LLP
14,966,264
7.04%
1,520,952
0.21%
06/30/2018
T. Rowe Price Associates, Inc.
10,990,628
5.17%
-3,872,275
0.11%
06/30/2018
BlackRock Fund Advisors
10,620,370
5%
-440,611
0.04%
06/30/2018
Capital Research & Management Co. (International Investors)
8,078,647
3.8%
733,970
0.62%
06/30/2018
SSgA Funds Management, Inc.
7,494,341
3.53%
92,337
0.04%
06/30/2018
Sands Capital Management LLC
4,773,209
2.25%
-4,995,489
0.9%
06/30/2018
Matrix Capital Management Co. LP
4,616,847
2.17%
598,900
9.13%
06/30/2018
UBS Securities LLC
4,357,403
2.04%
4,345,731
0.68%
06/30/2018
| Address |
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
|
|
Employees
|
- |
| Website |
http://www.incyte.com |
| Updated |
07/08/2019 |
| Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. |
